Full Text Journal Articles by
Author Arthi Vijayaraghavan

Advertisement

Find full text journal articles








The HI-STAR study: resource utilization and costs associated with serologic testing for antibody-positive patients at four United States medical centers.

Peter Mazonson, Molly Efrusy, Chris Santas, Alyssa Ziman, James Burner, Susan Roseff, Arthi Vijayaraghavan, Richard Kaufman,

<h4>Background</h4>Little is known about how the resource utilization and costs of serologic work ups for positive antibody screens vary across subpopulations based on diagnosis, transfusion history, and serologic testing history.<h4>Study design and methods</h4>Detailed data were collected on patient demographics, diagnoses, transfusion history, history of known allo- and autoantibodies, and specific ... Read more >>

Transfusion (Transfusion)
[2014, 54(2):271-277]

Cited: 5 times

View full text PDF listing >>



Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.

Arthi Vijayaraghavan, Molly B Efrusy, Burkhard Göke, Thomas Kirchner, Christopher C Santas, Richard M Goldberg,

The objective of this study was to determine the cost-effectiveness of testing for KRAS mutations before administering EGFR inhibitors such as cetuximab and panitumumab for patients with advanced metastatic colorectal cancer (mCRC) in the United States and Germany. We developed a lifetime Markov model of costs and survival associated with ... Read more >>

Int J Cancer (International journal of cancer)
[2012, 131(2):438-445]

Cited: 44 times

View full text PDF listing >>



Advertisement

Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.

Arthi Vijayaraghavan, Molly B Efrusy, Marie-Hélêne Mayrand, Christopher C Santas, Patricia Goggin,

<h4>Objectives</h4>Human papillomavirus (HPV) testing is not widely used for triage of equivocal Pap smears or primary screening in Québec, Canada. Our objective was to evaluate the cost-effectiveness of cervical cancer screening strategies utilizing HPV testing.<h4>Methods</h4>We used a lifetime Markov model to estimate costs, quality of life, and survival associated with ... Read more >>

Can J Public Health (Canadian journal of public health = Revue canadienne de sante publique)
[2010, 101(3):220-225]

Cited: 20 times

View full text PDF listing >>



Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

Arthi Vijayaraghavan, Molly B Efrusy, Karyn A Goodman, Christopher C Santas, Warner K Huh,

<h4>Objective</h4>Testing for human papillomavirus (HPV) 16 and 18 genotypes, which are known to cause approximately 65-70% of invasive cervical cancer cases, may allow clinicians to identify women at highest risk for underlying cervical intraepithelial neoplasia missed by Pap cytology. Our objective was to determine the cost-effectiveness of adding HPV-16 and ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2010, 119(2):237-242]

Cited: 10 times

View full text PDF listing >>



Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Arthi Vijayaraghavan, Molly Efrusy, Gerhard Lindeque, Greta Dreyer, Christopher Santas,

<h4>Objective</h4>To determine the cost effectiveness of several cervical cancer screening strategies utilizing HPV testing in South Africa.<h4>Methods</h4>We developed a lifetime Markov model of the costs, quality of life, and survival associated with screening and treating cervical cancer and its precursors. Screening strategies evaluated included: 1) conventional cytology, 2) cytology followed ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2009, 112(2):377-383]

Cited: 21 times

View full text PDF listing >>



Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.

Arthi Vijayaraghavan, Molly Bates Efrusy, Peter D Mazonson, Osman Ebrahim, Ian M Sanne, Christopher C Santas,

<h4>Objective</h4>Determine the cost-effectiveness of initiating and monitoring highly active antiretroviral therapy (HAART) in developing countries according to developing world versus developed world guidelines.<h4>Design</h4>Lifetime Markov model incorporating costs, quality of life, survival, and transmission to sexual contacts.<h4>Methods</h4>We evaluated treating patients with HIV in South Africa according to World Health Organization (WHO) ... Read more >>

J Acquir Immune Defic Syndr (Journal of acquired immune deficiency syndromes (1999))
[2007, 46(1):91-100]

Cited: 36 times

View full text PDF listing >>





Advertisement


Disclaimer

0.6498 s